Changes

Jump to: navigation, search

Autoimmune cytopenia

230 bytes added, 22:15, 13 November 2017
m
Alemtuzumab monotherapy {{#subobject:34416b|Regimen=1}}
|'''Study'''
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
|[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
|-
|[http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.2001.03039.x/full Willis et al. 2001]
|style="background-color:#EEEE00"|Phase II
|style="background-color:#b5b5b5"|ORR: 71%
|-
|}
To be completed
====Immunosuppressive therapy====
*[[Alemtuzumab (Campath)]]as follows:**Test dose: 1 mg IV over 1 hour once**Days 1 to 10: 10 mg IV over 4 hours once per day '''10-day course'''
===References===
# Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, Ouwehand W, Hale G, Waldmann H, Gordon-Smith EC. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001 Sep;114(4):891-8.[http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.2001.03039.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11564082 PubMed]
==Sirolimus monotherapy {{#subobject:35516b|Regimen=1}}==
LookupUsers, editors, emailconfirmed
24,251
edits

Navigation menu